Dr. Michael L. Cheng, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 89
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of California, Geffen School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A128157 (first issued 2013; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 1,318
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 161 | 55 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 105 | 48 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 70 |
| Alecensa (alectinib hcl) | 24 |
| Prochlorperazine Maleate Other prescribers in San Francisco, CA | 12 |
| Ondansetron Hcl Other prescribers in San Francisco, CA | 11 |
| Tepmetko (tepotinib hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 30 payments worth $4,630 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $1,834 |
|---|---|
| Janssen Biotech, Inc. | $1,350 |
| Merck Sharp & Dohme LLC | $1,213 |
| Pfizer Inc. | $132 |
| Genentech USA, Inc. | $68.00 |
| Genentech, Inc. | $32.94 |
| Travel and Lodging | $2,344 |
|---|---|
| Consulting Fee | $1,350 |
| Food and Beverage | $936 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 6, 2025 | Consulting Fee RYBREVANT · Oncology | $1,350 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $764 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $326 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $286 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $221 |
| Bayer HealthCare Pharmaceuticals Inc. May 1, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $170 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $170 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $154 |
| Bayer HealthCare Pharmaceuticals Inc. May 1, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $109 |
| Merck Sharp & Dohme LLC Feb 19, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA Company’s descriptionProvided as part of a clinical research engagement. | $65.62 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 6, 2025 | Consulting Fee RYBREVANT · Oncology | $1,350 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $764 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $47.98 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $170 |
| Bayer HealthCare Pharmaceuticals Inc. May 1, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $170 |
| Bayer HealthCare Pharmaceuticals Inc. May 1, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $109 |
| Bayer HealthCare Pharmaceuticals Inc. May 1, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $31.66 |
| Merck Sharp & Dohme LLC Feb 19, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA Company’s descriptionProvided as part of a clinical research engagement. | $65.62 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $326 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $286 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $154 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $221 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $178,078 in research payments for these studies, mostly to the institutions running them.
- A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc. - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - SRF388-101
Coherus Oncology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.